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OBJECTIVES This study was initiated to determine whether heart transplant recipients (HTRs) with
cardiac allograft vasculopathy (CAV) have increased levels of high-sensitivity C-reactive
protein (hsCRP) and to examine whether an increase in hsCRP after heart transplantation
predicts the development of CAV. Furthermore, the effect of pravastatin on plasma levels of
hsCRP in HTRs was investigated.
BACKGROUND The relationship between CAV and hsCRP, as well as the effect of statins on hsCRP in
HTRs, has not been well established.
METHODS On referral for their annual angiographic control study, 150 consecutive HTRs (mean 6.5
years since transplantation) were included. Plasma levels of hsCRP were measured before
angiography and compared with patients with (n  52) and without (n  98) CAV. In 49
of these patients, we additionally analyzed hsCRP in blood samples stored from their
six-month visit after the transplantation procedure. Furthermore, in a randomized, crossover
study, hsCRP was analyzed in 17 male HTRs before and after six weeks of treatment with
20 mg pravastatin.
RESULTS Median levels of CRP were elevated among patients with CAV compared with those with
normal angiograms [3.86 (1.78 to 7.00) vs. 1.08 (0.72 to 2.13) mg/l, p 0.001]. Prospectively
evaluated hsCRP levels from six months to follow-up were significantly higher among those
who developed CAV compared with those with normal angiograms [2.76 (1.56 to 5.00) vs.
0.07 (0.57 to 0.41) mg/l, p 0.001]. On multivariate analysis, the increase in hsCRP was
the only significant predictor of CAV. Six weeks of treatment with pravastatin significantly
reduced hsCRP levels by 25%, without any relation to changes in lipid values.
CONCLUSIONS Elevated plasma levels of CRP are associated with angiographic evidence of CAV, and the
increase in hsCRP is a strong predictor of development of CAV. Statin treatment reduces
levels of hsCRP and should be used in HTRs, regardless of their lipid levels. (J Am Coll
Cardiol 2003;42:477–82) © 2003 by the American College of Cardiology Foundation
Cardiac allograft vasculopathy (CAV), an accelerated and
diffuse form of coronary atherosclerosis, determines long-
term function of the transplanted heart and is the major
cause of death after the first year of heart transplantation (1).
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The disease is thought to be multifactorial in origin and has
been suggested to result most likely from initial and ongoing
immunologically mediated injury to the vascular endothe-
lium (2). The most common diagnostic tool of CAV
detection is routine annual coronary angiography, recom-
mended because cardiac ischemia can develop without
symptoms until severe cardiac dysfunction and death occur
(3,4). It is assumed that early detection of CAV may result
in the implementation of early surgical, percutaneous, or
medical life-saving therapies.
High-sensitivity C-reactive protein (hsCRP) is an acute-
phase protein and is a sensitive indicator of acute and
chronic inflammation occurring in the body. A growing
number of studies suggest that hsCRP is an independent
risk factor for native atherosclerotic disease (5). In a recent
morphologic report, hsCRP levels correlated with the se-
verity and extension of coronary artery disease (6). It has
also been suggested that elevated hsCRP levels predict
allograft failure (7). This raises the possibility of applying
the marker to identify high-risk patients for CAV, thus
reducing the regular screening angiography in otherwise
stable heart transplant recipients (HTRs).
The purpose of this study was to compare plasma levels of
hsCRP with angiographic evidence of CAV in a large
cohort of HTRs and to determine whether patients with
CAV have increased levels of hsCRP. We also wanted to
examine whether the increase in hsCRP after heart trans-
plantation can predict the development of CAV. Further-
more, it is well established that 3-hydroxy-3-methyl-
glutaryl coenzyme A reductase inhibitors (statins) protect
against CAV. Because this effect is not clearly attributable to
lipid lowering (8,9), we tested the effect of pravastatin on
inflammatory activity determined by plasma hsCRP levels,
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evident in most but not all reports on statin treatment in
native atherosclerosis (10,11).
METHODS
A total of 150 consecutive patients without signs of infec-
tion or acute rejection, who underwent routine annual
follow-up after heart transplantation, were entered into the
study between April 2001 and February 2002. The mean
time since transplantation was 6.5 years (range 1 to 16
years). All patients gave written, informed consent. The
indication for heart transplantation was end-stage heart
failure due to ischemic heart disease (n  64), idiopathic
cardiomyopathy (n  60), or miscellaneous disorders (con-
genital, valvular disease, myocarditis; n  26). Standard
triple-immunosuppressive therapy consisted of cyclospor-
ine, corticosteroids, and azathioprine. A statin has been
used routinely in our unit for all patients postoperatively
since 1997.
Venous blood samples were obtained from the patients
after an overnight fast before angiography was performed.
Blood samples were collected from an antecubital vein into
pyrogen-free tubes containing heparin (Becton Dickenson,
San Jose, California) and centrifuged at 1,400g for 10 min at
room temperature. The hsCRP was measured by an immu-
nonephelometric assay performed on the Behring nephe-
lometer (BN II, Dade Behring, Deerfield, Illinois). The
patients underwent routine annual coronary angiography.
Operators performing the procedure were blinded to
hsCRP measurements. The diagnosis of CAV was classified
as mild, moderate, or severe on the basis of involvement of
the left main coronary artery, primary-vessel stenosis, and
branch-vessel stenosis (12,13). Patients were categorized
into two groups: those with angiographically normal and
those with abnormal coronary arteries.
In a subgroup of 49 patients, blood samples stored at
80°C from their six-month visit after transplantation were
also analyzed for hsCRP. The increase in hsCRP from six
months to follow-up, with a mean follow-up of 4.8  1.7
years, was compared between those who developed CAV (n
 14) and those who did not (n  35).
In addition to the aforementioned investigations, we
analyzed hsCRP in 17 male HTRs (mean [SEM] age 53
 3 years) in an open-label, crossover design study, ran-
domized to receive either 20 mg pravastatin or no treatment
for six weeks. After a six-week washout period, patients
were crossed over. None of the patients participating in this
substudy had previously received statin treatment. The
mean time since transplantation in this group was 6 years
(range 1 to 15 years). Measurements were performed at
baseline, after six weeks of treatment, and after discontin-
uation of treatment.
Statistical analysis. Continuous data are presented as the
mean value (SD) for variables with normal distribution, as
the median value (interquartile range) for variables with a
skewed distribution, or as the frequency for categorical
variables. The skewness test was performed to evaluate
whether the data were normally distributed. The Student t
test was used to compare geometric mean values, whereas
the Mann-Whitney U test was used to compare median
values. Categorical variables were compared by chi-square
analysis. Logistic regression analysis was applied to identify
predictors of CAV, and the variables used were those which
gave significant differences between the two groups on
univariate analysis. A receiver-operating characteristics
(ROC) curve was generated to evaluate the accuracy of
hsCRP in the prediction of CAV (measured by the area
under the ROC curve, range 0.5 to 1). The median level of
hsCRP was selected as a cutoff point. A Kruskal-Wallis test
was performed to evaluate the association between hsCRP
levels and severity of CAV. In the crossover study, the
change in hsCRP was calculated as the median change
during treatment and after discontinuation, as compared
with baseline values. A p value 0.05 was considered
statistically significant.
RESULTS
Patient characteristics. Among the 150 patients included
in the study, 52 had angiographic evidence of CAV. A
history of ischemic heart disease and smoking was signifi-
cantly more frequent in the group with CAV (Table 1).
Furthermore, these patients were significantly older than
Abbreviations and Acronyms
BMI  body mass index
CAV  cardiac allograft vasculopathy
HLA  human leukocyte antigen
hsCRP  high-sensitivity C-reactive protein
HTR  heart transplant recipient
ROC  receiver-operating characteristics
Table 1. Patient Characteristics
CAV (n  52) CAV (n  98)
Age (yrs) 58  10 50  15*
Years since therapy 8.7  4.0 6.5  3.7*
Etiology (CAD/non-CAD) 34/18 42/56*
Gender (M/F) 43/9 75/23
BMI (kg/m2) 28.1  3.8 25.8  4.5*
Smokers 15/37 (29%) 10/88 (10%)*
Total cholesterol (mmol/l) 5.8  1.6 5.4  1.1
HDL cholesterol (mmol/l) 1.3  0.4 1.6  0.5*
Cyclosporine (g/l) 120.0  45.9 114.2  34.4
Creatinine (mol/l) 145.1  54.0 116.9  24.9*
Statin use 47/5 (90%) 85/13 (87%)
ASA use 20/32 (38%) 7/91 (7%)
Time of ischemia (min) 141.5  62.9 136.4  68.8
Donor age (yrs) 30.4  11.2 31  11.9
Gender mismatch 9/43 (17%) 28/70 (29%)
CMV mismatch 30/22 (58%) 46/52 (47%)
Data are presented as the mean value  SD or n/N (%) of patients.
ASA  acetyl salicyclic acid (aspirin); BMI  body mass index; CAD  coronary
artery disease; CAV  cardiac allograft vasculopathy; CMV  cytomegalovirus;
HDL  high-density lipoprotein.
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those with normal angiograms and had a significantly longer
time since transplantation, increased body mass index
(BMI), glycosylated hemoglobin, creatinine, and lower
high-density lipoprotein cholesterol levels (Table 1). There
was no difference in the numbers or severity of cellular
rejections between the two groups, nor was there any
difference regarding cytomegalovirus status, time of isch-
emia during the transplantation procedure, human leuko-
cyte antigen (HLA) mismatch, or donor age.
hsCRP and CAV. The median level of hsCRP for the
whole cohort was 1.66 mg/l (0.84 to 3.66). As assessed with
a similar technique in our laboratory, a median level of 0.90
mg/l was recently found in 105 healthy individuals (14).
Patients with evidence of CAV had significantly elevated
hsCRP levels compared with those with normal angiograms
[3.86 (1.78 to 7.00) and 1.08 (0.72 to 2.13) mg/l, p 
0.001] (Fig. 1). When classifying all patients into groups
according to increasing levels of CRP, a significant associ-
ation with the frequency of CAV was observed across
quartiles: 4 (11%), 8 (21%), 13 (34%), and 27 (75%) patients
with CAV, respectively (p  0.001 for trend), giving an
odds ratio between the fourth and first quartiles of 24.75
(95% confidence interval [CI] 6.86 to 89.31) (Fig. 2). The
ROC analysis indicated that hsCRP had reasonable accu-
racy for the development of CAV (Fig. 3). A cutoff point of
hsCRP at 1.66 mg/l gave a sensitivity of 77% and a
specificity of 64% for the development of CAV. There was
a significant trend toward higher hsCRP values in advanced
stages of CAV (Fig. 4).
Predictors of CAV and levels of hsCRP. On multivariate
analysis, using CAV as the dependent variable, hsCRP
together with patient age and time since transplantation
were significant predictors of CAV, whereas BMI was
borderline significant (Table 2). A significant interaction
between BMI and hsCRP was evident (p  0.001 for
interaction). Smoking was not an independent predictor of
CAV, but a significant interaction between smoking and
hsCRP was observed (p  0.02 for interaction).
Prospective study. Baseline hsCRP levels at six months
after transplantation did not differ between patients who
developed CAV and those with normal angiograms [1.37
(0.91 to 2.11) vs. 1.04 (0.61 to 1.97) mg/l, p NS], nor did
the time to follow-up (5.3  1.7 years vs. 4.8  1.8 years,
p  NS). In the former group, hsCRP levels increased
significantly from baseline to follow-up, compared with
patients without CAV [2.76 (1.56 to 5.00) mg/l vs. 0.07
(0.57 to 0.41) mg/l, p  0.001] (Fig. 5). On multivariate
analysis, the increase in hsCRP from baseline to follow-up
was the only significant predictor of CAV in this subgroup.
Figure 1. Levels of high-sensitivity C-reactive protein (hsCRP) among
patients with normal angiograms (squares) and patients with angiographic
evidence of cardiac allograft vasculopathy (CAV) (triangles). The hori-
zontal line indicates the median of the hsCRP values.
Figure 2. Numbers of patients with normal angiograms (lined bars) and with angiographic evidence of cardiac allograft vasculopathy (solid bars) in each
quartile of high-sensitivity C-reactive protein levels. The odds ratio between the first and fourth quartile is 24.75 (95% confidence interval 6.86 to 89.31).
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Crossover study. Six weeks of treatment with 20 mg
pravastatin significantly reduced hsCRP relative to baseline
values [from 2.21 (0.77 to 3.28) to 1.64 (0.81 to 2.35) mg/l,
p  0.01]. After another six weeks of washout, hsCRP
increased to baseline values [2.15 mg/l (0.79 to 6.65), p 
NS vs. baseline and p 0.01 vs. after 6 weeks of treatment].
Although pravastatin induced significant reductions in lev-
els of both total and low-density lipoprotein cholesterol (p
 0.01 for both), no correlation was found between changes
in lipids and hsCRP levels (data not shown).
DISCUSSION
This study demonstrates that HTRs with CAV can be
identified by higher plasma levels of hsCRP, compared with
those without angiographic evidence of disease. Further-
more, a long-term rise in hsCRP represents an independent
predictor of CAV development. The observed pravastatin-
mediated reductions in hsCRP levels extend the observation
of anti-inflammatory properties of statins in HTRs, sup-
porting their widespread prophylactic use in the prevention
of CAV.
hsCRP and CAV. Cardiac allograft vasculopathy results
from a complicated interplay between immunologic and
nonimmunologic factors, with consequent repetitive vascu-
lar injury and a localized sustained inflammatory response
(2). This vascular remodeling process involves the local
migration and proliferation of medial vascular smooth
muscle cells in response to inflammatory signals such as
cytokines and growth factor expression, with consequent
thickening of the intima (15). Elevated levels of hsCRP in
patients with CAV probably reflect these processes. The
pathogenesis of the inflammatory reactions leading to ele-
vated hsCRP is not known. Unlike another recent study (7),
we were unable to find any major differences between
Figure 3. The receiver operating characteristics (ROC) curve of high-
sensitivity C-reactive protein as a marker for cardiac allograft vasculopathy.
The ROC area was 0.80 (95% confidence interval 0.72 to 0.87; p 0.001).
Figure 4. Median levels of high-sensitivity C-reactive protein (hsCRP) by
severity of cardiac allograft vasculopathy (CAV).
Table 2. Multivariate Predictors of Cardiac Allograft Vasculopathy
Risk Factors for CAV OR 95% CI p Value
Age 1.07 1.01–1.13 0.029
Years since transplantation 1.23 1.07–1.42 0.004
Etiology 0.63 0.23–1.63 0.327
BMI 1.14 0.99–1.32 0.064
Smoking 2.75 0.77–10.82 0.147
HDL cholesterol 0.44 0.11–1.72 0.241
Creatinine 1.01 0.99–1.03 0.292
hsCRP 1.31 1.06–1.61 0.012
CI  confidence interval; hsCRP  high-sensitivity C-reactive protein; OR  odds
ratio; other abbreviations as in Table 1.
Figure 5. Delta values (expressed as mean values) of high-sensitivity
C-reactive protein (hsCRP) from baseline to follow-up among patients
with normal angiograms (cardiac allograft vasculopathy [CAV]) and in
patients with angiographic evidence of CAV (CAV).
480 Hognestad et al. JACC Vol. 42, No. 3, 2003
C-Reactive Protein in HTRs August 6, 2003:477–82
patients with and without CAV regarding immunologic
factors such as HLA mismatch and the number of cellular
rejections, or nonimmunologic risk factors such as donor
characteristics, time of ischemia, and cytomegalovirus infec-
tion. Interestingly, traditional risk factors in the develop-
ment and progression of atherosclerosis were present in the
group with CAV. Although smoking was not an indepen-
dent predictor of CAV in our study, a significant interaction
between smoking and hsCRP was observed. It has previ-
ously been shown that smoking is associated with an
increase in CRP (16) and with intima-media thickness in
carotid arteries (17). Thus, despite a lack of a direct
relationship between smoking and CAV in our study,
smoking could increase hsCRP, either by nurturing inflam-
mation or by other not yet identified mechanisms. The
mechanism by which BMI predisposes to CAV is not clear.
Adipose tissue produces interleukin-6, which has pro-
inflammatory properties by stimulating acute-phase proteins
in the liver (18). This may explain the observed interaction
between hsCRP and BMI. Further, it is well known that
high-density lipoprotein cholesterol has a protective role in
native atherosclerosis. Even though conventional athero-
sclerotic risk factors do not necessarily predict the develop-
ment of CAV, it has been shown that metabolic abnormal-
ities are associated with more severe vasculopathy (19,20),
findings that are supported by this study. In fact, CAV
development was recently shown to develop in a rat model
where there were no major or minor histocompatibility
mismatches (21), highlighting the importance of nonim-
mune factors. In concordance with other studies (13,22,23),
we also found that older age and pretransplant ischemic
heart disease was more frequent among patients with CAV.
We do not know if the inflammation reflected by hsCRP
is the cause of CAV or whether it is just a manifestation of
the disease. Instead of being just a marker for systemic
inflammation, CRP may also have a pathogenetic role. It
has been shown that CRP can activate complement and
stimulate production of tissue factor by mononuclear cells
(24). In addition, elevated levels of hsCRP are associated
with impaired systemic endothelial vascular reactivity in
patients with native atherosclerosis (25), and endothelial
dysfunction is believed to contribute to progression of
coronary artery disease and to future cardiovascular events
(26,27). Reduced endothelium-dependent vasodilation is
well documented also in HTRs (28), and the observed
relationship between hsCRP and CAV in this study may
partly be explained by this phenomenon. This is further
supported by Labarrere et al. (29), who showed that elevated
hsCRP was associated with increased levels of intercellular
adhesion molecule-1. It was previously shown that CRP
induces expression of intercellular adhesion molecule-1 in
coronary artery endothelial cells (30). Without challenging
the view of an early perioperative insult to the endothelium
as the initial trigger, our prospective investigation of hsCRP
underlines the importance of individual chronic inflamma-
tory responses leading to CAV. We found that hsCRP is
markedly elevated in patients with emerging CAV, and it
seems to be a quantitative marker of the progression of the
disease. These findings are in concordance with two other
recent studies (29,31) and give additional support to the
association between CAV and systemic inflammation.
Whether elevated hsCRP is a risk marker or a risk factor
will only be settled by future studies.
In search of improved noninvasive indicators and tech-
niques that can more clearly define the groups of patients at
higher risk for CAV (4), our study findings could have
clinical implications in terms of reducing the number of
angiographic procedures. Because high levels of hsCRP
seem to represent a marker of CAV development in
individual patients, transplant centers should include this
measurement in their routine blood samples. Due to the
degree of overlap between values in patients with and
without CAV, hsCRP determination is not suitable as a
single noninvasive parameter in deciding the need for
invasive procedures. However, a role of hsCRP levels as an
ancillary method for exclusion of CAV seems justified, so
that there is a less rigid use of angiography in these patients.
Statins and hsCRP. Our demonstration of a median 25%
reduction of hsCRP after only six weeks of treatment with
a relatively low dose of pravastatin in HTRs, is at least as
affective as the results achieved in native atherosclerosis and
hyperlipidemia (32,33). Furthermore, the observation adds
this patient group to those with various forms of cardiovas-
cular disease, where this phenomenon has been docu-
mented. Although it seems a common trait among different
statins, not all patients with latent or manifest cardiovascu-
lar disease respond to statins with lowering of hsCRP
(10,11). In familial hypercholesterolemia, levels of hsCRP
were reported to be higher in those with than in those
without atherosclerotic disease, but statin treatment over
one year had no significant effect on hsCRP levels (10). It
could be speculated that the inflammatory aspect is more
essential among HTRs than in familial hypercholesterol-
emia. The recent demonstration of reductions in levels of
proinflammatory cytokines and improvement of coronary
endothelial function with statin treatment after heart trans-
plantation suggests their important roles in improving graft
survival and reducing CAV in long-term postoperative
treatment with statins (34). Alterations in endogenous
factors such as cytokines seem a plausible mechanism by
which statins reduce hsCRP levels also in HTRs, rather
than by increasing the clearance or reducing the synthesis of
hsCRP.
Study limitations. Characterization of CAV was per-
formed by semi-quantitative angiographic grading. It is
known from intravascular ultrasound studies that these
results can be misleading in terms of a possible underesti-
mation of intimal hyperplasia and vascular remodeling
(31,35). Thus, it cannot be determined whether the rela-
tionship between hsCRP and CAV would have been
strengthened or weakened by the latter technique.
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Conclusions. Elevated plasma levels of hsCRP are associ-
ated with angiographic evidence of CAV, and the increase
in hsCRP during follow-up of HTRs is a strong predictor of
the development of CAV. These findings demonstrate the
importance of inflammation in this disease, and hsCRP
could be used as an ancillary marker for detection of CAV
during follow-up of HTRs. Statin treatment reduces levels
of hsCRP in these patients, giving further evidence of their
ability to lower inflammatory activity, leading to fewer cases
of CAV. Our results concur with the recent report of
Labarrere et al. (29) and can be extended to have clinical
implications in that pravastatin decreases hsCRP in HTRs.
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